Drug Discovery

Spark Therapeutics, Pfizer amend license deal for investigational SPK-9001 in hemophilia B

Spark Therapeutics and Pfizer have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B.

Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases

Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.

Boehringer, Dicerna partner on RNAi treatment for NASH

Boehringer Ingelheim and Dicerna Pharmaceuticals have partnered to develop treatments for chronic liver diseases including Nonalcoholic Steatohepatitis (NASH).

Aviragen Therapeutics and Vaxart sign merger deal

Aviragen Therapeutics, which is engaged in the discovery and development of direct-acting antivirals to treat infections with limited therapeutic options, has signed a merger agreement with Vaxart, a clinical-stage company focused on developing oral recombinant vaccines.

Voyager to gain global rights to VY-AADC program for advanced Parkinson’s disease

Voyager Therapeutics, a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, has announced an update to its VY-AADC program for advanced Parkinson’s disease.

Researchers identify new genetic variants for breast cancer risk

A major international collaboration involving hundreds of researchers worldwide has identified seventy-two new genetic variants that contribute to the risk of developing breast cancer.

Incyte, MacroGenics sign licensing agreement for anti-PD-1 monoclonal antibody MGA012

Incyte and MacroGenics have entered into an exclusive global collaboration and license agreement for MacroGenics’ MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

Aurinia to expand voclosoprin renal franchise

Aurinia Pharmaceuticals revealed plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).

Boehringer Ingelheim partners with TARGET to progress NASH research

TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH.